Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study.

Ann Med · 2025 · PMC12517412 · PMID 41074585

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

showed a trendp = 0.069so close (0.05 < p ≤ 0.1)

Moreover, patients with the initial IHC 3+ showed a trend toward a higher ORR compared to those with IHC 2+ (61.5% vs. 30.4%, p = 0.069) ( Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.